1. Executive Summary |
2. Global Lung Cancer Therapeutics Market Introduction |
2.1. Global Lung Cancer Therapeutics Market – Taxonomy |
2.2. Global Lung Cancer Therapeutics Market –Definitions |
2.2.1. By Treatment Type |
2.2.2. By Disease Type |
2.2.3. By Distribution Channel |
2.2.4. By Region |
3. Global Lung Cancer Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Lung Cancer Therapeutics Market Dynamic Factors – Impact Analysis |
3.6. Global Lung Cancer Therapeutics Market – Competition Landscape |
3.7. Epidemiology |
4. Global Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 |
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Lung Cancer Therapeutics Market, By Treatment Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.1. Targeted Therapy |
5.1.1. Bevacizumab |
5.1.1.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn) |
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.1.3. Market Opportunity Analysis |
5.1.2. Dabrafenib/Trametinib |
5.1.2.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn) |
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.2.3. Market Opportunity Analysis |
5.1.3. Erlotinib |
5.1.3.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn) |
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3.3. Market Opportunity Analysis |
5.1.4. Osimertinib |
5.1.4.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn) |
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.4.3. Market Opportunity Analysis |
5.1.5. Others |
5.1.5.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn) |
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.5.3. Market Opportunity Analysis |
5.2. Immunotherapy |
5.2.1. Durvalumab |
5.2.1.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn) |
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.1.3. Market Opportunity Analysis |
5.2.2. Nivolumab |
5.2.2.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn) |
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.2.3. Market Opportunity Analysis |
5.2.3. Atezolizumab |
5.2.3.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn) |
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3.3. Market Opportunity Analysis |
5.2.4. Pembrolizumab |
5.2.4.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn) |
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.4.3. Market Opportunity Analysis |
5.3. Chemotherapy |
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Lung Cancer Therapeutics Market, By Disease Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.1. Non-small Cell Lung Cancer (NSCLC) |
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Small Cell Lung Cancer (SCLC) |
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Lung Cancer Therapeutics Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Lung Cancer Therapeutics Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.1. North America |
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Region, 2022 – 2028 |
9. North America Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
9.1. Treatment Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Targeted Therapy |
9.1.1.1. Bevacizumab |
9.1.1.2. Dabrafenib/Trametinib |
9.1.1.3. Erlotinib |
9.1.1.4. Osimertinib |
9.1.1.5. Others |
9.1.2. Immunotherapy |
9.1.2.1. Durvalumab |
9.1.2.2. Nivolumab |
9.1.2.3. Atezolizumab |
9.1.2.4. Pembrolizumab |
9.1.3. Chemotherapy |
9.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Non-small Cell Lung Cancer (NSCLC) |
9.2.2. Small Cell Lung Cancer (SCLC) |
9.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.3.1. Hospital Pharmacies |
9.3.2. Retail Pharmacies |
9.3.3. Online Pharmacies |
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. USA |
9.4.2. Canada |
9.5. North America Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2022 – 2028 |
9.6. North America Lung Cancer Therapeutics Market Dynamics – Trends |
10. Europe Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
10.1. Treatment Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Targeted Therapy |
10.1.1.1. Bevacizumab |
10.1.1.2. Dabrafenib/Trametinib |
10.1.1.3. Erlotinib |
10.1.1.4. Osimertinib |
10.1.1.5. Others |
10.1.2. Immunotherapy |
10.1.2.1. Durvalumab |
10.1.2.2. Nivolumab |
10.1.2.3. Atezolizumab |
10.1.2.4. Pembrolizumab |
10.1.3. Chemotherapy |
10.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Non-small Cell Lung Cancer (NSCLC) |
10.2.2. Small Cell Lung Cancer (SCLC) |
10.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Hospital Pharmacies |
10.3.2. Retail Pharmacies |
10.3.3. Online Pharmacies |
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Spain |
10.4.5. Italy |
10.4.6. Russia |
10.4.7. Rest of Europe |
10.5. Europe Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2022 – 2028 |
10.6. Europe Lung Cancer Therapeutics Market Dynamics – Trends |
11. Asia-Pacific Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
11.1. Treatment Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Targeted Therapy |
11.1.1.1. Bevacizumab |
11.1.1.2. Dabrafenib/Trametinib |
11.1.1.3. Erlotinib |
11.1.1.4. Osimertinib |
11.1.1.5. Others |
11.1.2. Immunotherapy |
11.1.2.1. Durvalumab |
11.1.2.2. Nivolumab |
11.1.2.3. Atezolizumab |
11.1.2.4. Pembrolizumab |
11.1.3. Chemotherapy |
11.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Non-small Cell Lung Cancer (NSCLC) |
11.2.2. Small Cell Lung Cancer (SCLC) |
11.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Hospital Pharmacies |
11.3.2. Retail Pharmacies |
11.3.3. Online Pharmacies |
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. China |
11.4.2. India |
11.4.3. Japan |
11.4.4. ASEAN |
11.4.5. Australia & New Zealand |
11.4.6. Rest of Asia-Pacific |
11.5. Asia-Pacific Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2022 – 2028 |
11.6. Asia-Pacific Lung Cancer Therapeutics Market Dynamics – Trends |
12. Latin America Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
12.1. Treatment Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Targeted Therapy |
12.1.1.1. Bevacizumab |
12.1.1.2. Dabrafenib/Trametinib |
12.1.1.3. Erlotinib |
12.1.1.4. Osimertinib |
12.1.1.5. Others |
12.1.2. Immunotherapy |
12.1.2.1. Durvalumab |
12.1.2.2. Nivolumab |
12.1.2.3. Atezolizumab |
12.1.2.4. Pembrolizumab |
12.1.3. Chemotherapy |
12.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Non-small Cell Lung Cancer (NSCLC) |
12.2.2. Small Cell Lung Cancer (SCLC) |
12.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Hospital Pharmacies |
12.3.2. Retail Pharmacies |
12.3.3. Online Pharmacies |
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Mexico |
12.4.3. Argentina |
12.4.4. Rest of Latin America |
12.5. Latin America Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2022 – 2028 |
12.6. Latin America Lung Cancer Therapeutics Market Dynamics – Trends |
13. Middle East and Africa Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
13.1. Treatment Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Targeted Therapy |
13.1.1.1. Bevacizumab |
13.1.1.2. Dabrafenib/Trametinib |
13.1.1.3. Erlotinib |
13.1.1.4. Osimertinib |
13.1.1.5. Others |
13.1.2. Immunotherapy |
13.1.2.1. Durvalumab |
13.1.2.2. Nivolumab |
13.1.2.3. Atezolizumab |
13.1.2.4. Pembrolizumab |
13.1.3. Chemotherapy |
13.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Non-small Cell Lung Cancer (NSCLC) |
13.2.2. Small Cell Lung Cancer (SCLC) |
13.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Hospital Pharmacies |
13.3.2. Retail Pharmacies |
13.3.3. Online Pharmacies |
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Gulf Cooperation Council (GCC) Countries |
13.4.2. Israel |
13.4.3. South Africa |
13.4.4. Rest of MEA |
13.5. MEA Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2022 – 2028 |
13.6. MEA Lung Cancer Therapeutics Market Dynamics – Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. F. Hoffmann-La Roche Ltd |
14.2.2. Eli Lilly and Company |
14.2.3. Celgene Corporation |
14.2.4. AstraZeneca plc |
14.2.5. Pfizer, Inc. |
14.2.6. Sanofi SA |
14.2.7. Novartis AG |
14.2.8. Bristol Myers Squibb |
14.2.9. Merck MSD |
14.2.10. Millennium Pharmaceuticals, Inc. |
15. Research Methodology |
16. Key Assumptions and Acronyms |